On August 30, 2017, Liaoyuan City's first science and technology association organized by a non-public enterprise was established within the company. Ma Xiujun, Chairman of the Municipal Science and Technology Association, along with Li Xiuwu, Deputy Minister of the Municipal United Front Work Department and Party Secretary of the Municipal Federation of Industry and Commerce, attended the founding conference and delivered important speeches. The Science and Technology Association of Jilin Boda Weiye Pharmaceutical Co., Ltd. is a mass organization voluntarily formed by the company's scientific and technological professionals. It serves as a vital bridge and link between the company's Party organization, management decision-making bodies, and its tech-savvy employees, playing a crucial role in driving technological advancement and innovation within the company. Since its establishment, Jilin Boda Weiye Pharmaceutical Co., Ltd. has consistently upheld its mission to respect life and safeguard human health. Guided by the core values of embracing the finest scientific and technological achievements to build a century-old legacy, the company leverages two cutting-edge R&D platforms—biopharmaceuticals and chemical drugs. As the chairman unit of the Jilin Province Chemical Drug Industry Technology Innovation Strategic Alliance and the Jilin Province Chemical Drug Pilot Testing Center, the company is dedicated to the comprehensive development of biochemical and biopharmaceutical products, focusing on the research, production, and distribution of medicines targeting cardiovascular, digestive, anti-cancer, and neuropsychiatric conditions. The company boasts advanced production facilities that meet the latest GMP standards, equipped with state-of-the-art imported and domestically sourced equipment. These include a 3,500-ton annual capacity active pharmaceutical ingredient (API) production line, a 50-million-vial annual output line for biological preparations, a 20-million-vial annual production line for large-volume infusions, an 80-million-vial annual line for small-volume injections, and a 3-billion-tablet annual solid dosage form production line. Notably, the company’s independently developed, next-generation Class III national new drug—Pupureizinc, designed specifically for treating gastric ulcers—has gained widespread recognition from clinicians and medical experts, earning high praise and strong patient acceptance since its market launch. In 2012, this innovative product was honored as one of China’s Top Ten Key Prescription Drugs at the 68th National Pharmaceutical Fair. Additionally, it was officially recognized as a Jilin Provincial Famous Brand Product following deliberation by the Jilin Provincial Brand Promotion Committee. Currently, the company has successfully commercialized and industrialized 15 innovative drug formulations, with another 16 undergoing approval processes at the National Medical Products Administration. Furthermore, the company is actively pursuing the development of 6 additional pipeline projects. Together, these initiatives have enabled the company to establish a robust strategic framework: producing today’s innovations while simultaneously nurturing future breakthroughs and maintaining a steady pipeline of cutting-edge R&D efforts.